Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Significant Decline in Short Interest

Esperion Therapeutics, Inc. (NASDAQ:ESPRGet Free Report) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 35,390,000 shares, a drop of 5.6% from the September 30th total of 37,470,000 shares. Based on an average trading volume of 3,640,000 shares, the days-to-cover ratio is presently 9.7 days. Currently, 18.2% of the company’s shares are sold short.

Esperion Therapeutics Stock Performance

Shares of NASDAQ ESPR traded down $0.07 during trading on Thursday, hitting $2.06. The company had a trading volume of 1,788,177 shares, compared to its average volume of 6,157,103. Esperion Therapeutics has a 12 month low of $0.79 and a 12 month high of $3.40. The firm has a market capitalization of $390.29 million, a P/E ratio of -2.15 and a beta of 1.00. The stock has a 50 day simple moving average of $1.86 and a 200 day simple moving average of $2.12.

Esperion Therapeutics (NASDAQ:ESPRGet Free Report) last released its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million for the quarter, compared to analysts’ expectations of $51.90 million. As a group, analysts predict that Esperion Therapeutics will post -0.04 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ESPR. Needham & Company LLC cut their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Wednesday, October 2nd. Finally, StockNews.com upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, October 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.17.

Get Our Latest Stock Report on ESPR

Institutional Trading of Esperion Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BOKF NA bought a new stake in shares of Esperion Therapeutics in the second quarter worth about $26,000. Traphagen Investment Advisors LLC purchased a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $27,000. Xponance Inc. bought a new position in shares of Esperion Therapeutics during the 2nd quarter valued at approximately $28,000. CVI Holdings LLC purchased a new position in shares of Esperion Therapeutics in the first quarter valued at $37,000. Finally, Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics in the second quarter worth $44,000. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Recommended Stories

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.